John J. Canepa - 28 Feb 2022 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Role: Chief Financial Officer
Signature: /s/ John Canepa
Issuer symbol: CADL
Transactions as of: 28 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 01 Mar 2022, 17:40:38 UTC
Previous filing: 02 Aug 2021
SEC: View on sec.gov

Quoteable Key Fact

"John J. Canepa filed Form 4 for Candel Therapeutics, Inc. (CADL) on 01 Mar 2022."

Quick Takeaways

This page summarizes John J. Canepa's Form 4 filing for Candel Therapeutics, Inc. (CADL).
1 reported transaction and 1 derivative row are listed below.
Filing timestamp: 01 Mar 2022, 17:40.

What Changed

Previous filing in this sequence was filed on 02 Aug 2021.
Current net transaction value: $0.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CADL	Stock Option (Right to Buy)	Award	$0	+110,000		$0.000000	110,000	28 Feb 2022	Common Stock	110,000	$4.12	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option is subject to time-based and performance-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following the Grant Date, subject to the Reporting Person's continued service on each such vesting date; provided, however, that one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $13.50 for any ten consecutive trading days prior to or as of December 31, 2022, and an additional one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $20.00 for any ten consecutive trading days prior to or as of December 31, 2022.

Content

This option is subject to time-based and performance-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following the Grant Date, subject to the Reporting Person's continued service on each such vesting date; provided, however, that one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $13.50 for any ten consecutive trading days prior to or as of December 31, 2022, and an additional one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $20.00 for any ten consecutive trading days prior to or as of December 31, 2022.